Beryl Drugs Ltd

• Board meeting held on 9 Feb 2026, concluded at 4:30 PM • EOGM scheduled for 16 Mar 2026 • EOGM to regularise appointment of Whole-Time Director & Independent Director • Approved unaudited Q3 FY26 financial results and noted auditor's limited review report

📋 Board Meeting and EOGM Announcement

The company held its board meeting on 9 February 2026 from 2:00 PM to 4:30 PM.

🗓️ EOGM Announcement

• An Extraordinary General Meeting (EOGM) is scheduled for 16 March 2026.
• Purpose of the EOGM:
  • Regularise the appointment of Mr. Shailendra Pathak as Whole-Time Director
  • Fix his role, responsibilities, and remuneration
  • Approve the appointment of Mrs. Neha Sarda as an Independent Director
  • Approval of material related party transactions with M/s. Aminova Infusions Pvt. Ltd., where Mr. Pathak owns 50% equity.

💼 Director Appointments

Regularising appointments means formal confirmation of their roles and responsibilities, ensuring clarity on governance and operational leadership.

📊 Financial Results

• Unaudited financial results for the quarter ended 31 December 2025 were considered and approved.
• The auditors' limited review report on these results was noted, offering preliminary assurance on their accuracy.

⚖️ What This Means

• Formalising key director appointments indicates standard corporate governance activities.
• Approval of related party transactions enhances transparency regarding dealings with entities connected to directors.
• Approving quarterly financial results and auditor reviews keeps investors informed about recent company performance.

These steps are typical for compliance and transparency in company operations, ensuring accountability and regulatory alignment.